Welcome to our dedicated page for Conformis news (Ticker: CFMS), a resource for investors and traders seeking the latest updates and insights on Conformis stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Conformis's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Conformis's position in the market.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Conformis, Inc. (NASDAQ: CFMS), a prominent medical device company specializing in personalized knee and hip replacements, is scheduled to announce its first-quarter financial results for the period ending March 31, 2023, on May 8, 2023, before the market opens. CEO Mark Augusti and CFO Bob Howe will lead a conference call at 8:30 a.m. Eastern Time to discuss the results and offer a business update. Interested parties can access the earnings call via a live webcast or by telephone, with registration required for telephone access. Conformis is dedicated to enhancing orthopedic patient care through innovative, personalized medical solutions, ensuring choices for surgeons and patients alike.
Conformis, Inc. (NASDAQ:CFMS) has launched a patient education campaign focusing on the importance of patient choice in total knee arthroscopy. The initiative aims to inform patients about the differences between traditional knee implants and personalized systems, which are made using advanced 3D imaging technology. The campaign, running in the Boston and Minneapolis-St. Paul areas, highlights that personalized implants can result in higher patient satisfaction, bone preservation, and lower hospital costs. More than 50 studies support the benefits of fully personalized implants, including reduced recovery times and fewer corrective surgeries.
Conformis, Inc. (CFMS) reported Q4 2022 revenues of $17.4 million, a 13% increase year-over-year, driven by growth in royalty and licensing revenue. Product revenue decreased 7% year-over-year to $14.2 million, with hip system revenue down 15% at $0.6 million. Total revenue for 2022 was $62.1 million, reflecting a significant 38% decline largely due to non-recurring licensing revenue in 2021. Cash reserves stood at $48.7 million, down from $59.6 million in Q3 2022. The company expects Q1 2023 product revenue to range between $12 million and $13 million, impacted by ongoing transition and supply chain challenges.
BILLERICA, Mass., Feb. 21, 2023 – Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company, announced participation in two upcoming investor conferences. On March 8, at the 43rd Annual Cowen Healthcare Conference, management will engage in a fireside chat from 11:10 a.m. to 11:40 a.m. EST. On March 14, during the 33rd Annual Oppenheimer Healthcare Conference, a presentation is scheduled from 8:40 a.m. to 9:10 a.m. EST. Live webcasts will be available, with replays accessible for 30 days. Conformis aims to enhance orthopedic patient care through personalized solutions.
Conformis Inc. (NASDAQ:CFMS) and Bodycad Laboratories have settled a patent infringement dispute initiated in June 2021. The settlement involves an undisclosed financial agreement, allowing both companies to dismiss all litigation and grant licenses related to Conformis' patents for patient-specific instruments and knee implants. This resolution is aimed at fostering innovation in orthopedic patient care, which aligns with Conformis' mission to offer personalized solutions through its Image-to-Implant® program and Surgery-in-a-Box™ delivery system.
Conformis (NASDAQ:CFMS) has unveiled a new advertising campaign emphasizing its Image-to-Implant Platinum Services program aimed at personalized knee replacements. As of December 31, 2022, 154 facilities have accessed this program, with over 500 orders received. In preliminary results for Q4 2022, total revenue reached approximately $17.4 million, up 13% year-over-year, boosted by non-recurring licensing revenue. However, product revenue declined by 7% to $14.2 million. For the full year, total revenue dropped 38% to $62.1 million. Looking ahead, Q1 2023 product revenue is anticipated to be between $12 million and $13 million, amid challenges during the business model transition.
